CS1P1 PET Studies of Neuroinflammation in Parkinson Disease
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- PET imaging studies of [11C]-CS1P1 in healthy control participants and participants with Parkinson Disease.
研究概览
简要总结
Parkinson disease (PD) is a progressive neurological disorder strongly linked to advancing age that results in decline in mobility and thinking. Based on prior research, the investigators think that small amounts of inflammation in the brain may contribute to the mobility and thinking problems in people with PD. They are trying to measure inflammation in the brain in order to understand how this inflammation could be contributing to the symptoms of PD. This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called [11C]-CS1P1 to identify inflammation in the brain.The goal of this project is to quantify neuroinflammation with [11C]-CS1P1 PET and compare to motor and cognitive function in participants with various stages of severity of PD compared to controls.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Parkinson Disease (PD) participants must be at least 50 years old and meet clinical diagnostic criteria of idiopathic PD.
- •Control participants must be at least 50 years old and not have PD, no first-degree family member with PD, and no evidence of PD or dementia on examination.
排除标准
- •any history of other neurologic illness (e.g. stroke, seizure, multiple sclerosis)
- •history of brain surgery or major head trauma
- •major medical/systemic illness
- •severe psychiatric illness (e.g. bipolar disorder, schizophrenia)
- •major drug abuse
- •history of long term use of anti-dopaminergic medication
- •chronic treatment with immunomodulatory or anti-inflammatory medications
- •weight over 300 lbs
- •contraindication to or inability to tolerate MRI
研究组 & 干预措施
Parkinson Disease
干预措施: [11C]-CS1P1 (Drug)
Healthy Control
干预措施: [11C]-CS1P1 (Drug)
结局指标
主要结局
PET imaging studies of [11C]-CS1P1 in healthy control participants and participants with Parkinson Disease.
时间窗: At the time of PET scan
The investigators hypothesize that specific binding of \[11C\]-CS1P1 is elevated in participants with neurodegenerative disease of the central nervous system compared to healthy control participants.
次要结局
未报告次要终点